Bhikaji Cama, a hero of India's freedom, was the first to unfurl the Indian tricolour on foreign soil.
Covaxin is an anti-coronavirus vaccine of Bharat Biotech
Twenty-four deaths, including that of 12 infants, have been reported in the last 24 hours in a government hospital in Nanded, a top Maharashtra health official said on Monday.
The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
500 million doses per annum from its two sites in Hyderabad and 200 million doses each from its Ankleshwar and Kolar facilities.
This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.
India is expecting 156 million doses of the vaccine from August to September, reports Ruchika Chitravanshi.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
'Even if Serum Institute and Bharat Biotech were successful in ramping up production overnight, what happens to the capacity after the demand from India is met?' asks Sanjeev Nayyar.
'What proportion of the people require the vaccine for us to manage this entire COVID-19 situation?'
Manjula Chimbalkar, a health coordinator from Mumbai's COVID-19 hotspot Dharavi, speaks about her concerns and fears
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances